Request ConsultationGene therapy is changing how doctors treat rare genetic diseases by targeting the root cause of these conditions. Advances in gene editing, delivery technologies, and AI are helping expand treatment possibilities.
Rare diseases affect a small percentage of the population, but their collective impact is quite profound. Gene therapy is transforming treatment paradigms by helping to modify, replace, or repair defective genes, making it particularly effective for monogenic disorders. It mainly makes use of two primary delivery approaches: in vivo, where therapeutic genes are directly delivered into a patient’s cells using viral or non-viral vectors, and ex vivo, where cells are extracted, genetically modified outside the body, and then reintroduced, an approach that is commonly used for hematologic disorders.
Cell and gene therapies (CGTs) are reshaping what it means to treat disease. Instead of managing symptoms over a lifetime, these approaches aim to address disease at its source by correcting, replacing, silencing, or supplementing faulty biological instructions, or by using living cells as therapeutic tools. For rare diseases, many of which are driven by genetic mutations and have few effective treatment options, this shift is especially significant.
With rapid advancements in gene-editing technologies like CRISPR, next-generation sequencing, and AI-powered analytics, the future of rare disease treatment is becoming increasingly personalized and effective. While certain challenges to widespread adoption persist, continued collaboration between researchers, healthcare providers, and policymakers will prove to be vital in unlocking the full potential of these transformative therapies.
What is Gene Therapy?
Gene therapy is a treatment for the treatment of genetic disorders. It works by changing a disease-causing gene or providing a working copy of that gene. Genes contain instructions for making proteins that help your body function.
Genetic diseases can occur when a gene changes in a way that prevents it from working or causes it to produce faulty proteins. You may be born with a gene change or develop one during your lifetime. Gene therapies are often one-time treatments that help your body produce the proteins it needs to function properly and reduce disease symptoms.
Some diseases result from a known genetic defect or gene mutation. This means there is a hereditary or acquired error in the DNA molecule that contains the code for producing a specific protein in the body. The altered protein does not function as it should, causing disease. Gene therapy aims to direct the body to produce healthy proteins that do not cause disease.
This therapy involves delivering DNA or RNA. RNA is an intermediate molecule formed during protein production. The genetic defect responsible for some diseases has been identified, but many genetic mutations remain unknown and may be identified in the future.
Research is ongoing into ways to correct genetic defects associated with certain diseases. Researchers are investigating different types and methods of gene therapy.
Gene therapy works by either changing how the disease-causing gene works or providing a working copy of the gene to make a protein your body needs. Some methods of gene therapy include:
- Gene addition: Gene addition inserts a working copy of a gene into your cells. This method can be used if a gene change is preventing your cells from making enough of a certain protein.
- Gene editing: In order to edit a gene, scientists use special tools, like CRISPR/cas9, to change a disease-causing gene so that it makes the correct protein.
- Gene silencing: Silencing “turns off” a disease-causing gene. This approach helps to silence a gene that prevents a normal protein from doing its job, or one that isn’t working properly, hence causing the disease.
What Conditions Does Gene Therapy Treat?
Gene therapies work best on genetic conditions caused by a change to a single gene. Conditions with approved gene therapy treatments include:
- Cerebral adrenoleukodystrophy.
- Inherited blood disorders, like sickle cell disease, thalassemia, and hemophilia.
- Inherited neuromuscular disorders, like Duchenne muscular dystrophy and spinal muscular atrophy.
- Inherited retinal (eye) diseases, like Leber’s congenital amaurosis.
- Metachromatic leukodystrophy.
Scientists and healthcare professionals are also investigating gene therapy to treat many other genetic conditions, as well as HIV and cancer.
What Happens During Gene Therapy?
What takes place during an individual’s gene therapy treatment depends on the kind of approach they are receiving. They will either get a shot or an infusion, where the treatment goes directly into a vein with an IV.
One might need to prepare for the treatment by getting:
- Genetic testing to confirm you have a specific gene change
- Blood tests
- Chemotherapy or other treatments
- A blood draw or bone marrow procedure to get stem cells that’ll be prepared for gene therapy
Why Is Gene Therapy Done?
Some gene mutations direct the body to make disease-causing proteins. And some genetic mutations are not functional; they cause disease because the body lacks the healthy proteins that should be normally produced by the gene.
Gene therapy aims to direct the body to produce healthy proteins or to inhibit the production of defective proteins. This also depends on the type of mutation that is causing the disease.
Why Rare Diseases Are Driving Gene Therapy Innovation
Rare diseases are a proving ground for medical innovation, shaping breakthroughs in genomics, gene therapy, AI, and precision medicine. Stronger, interoperable data foundations can now help to accelerate diagnosis, unlock new treatments, reduce costs, and improve overall outcomes. By investing in better data, smarter regulation, and cross-border collaboration, rare disease innovation can benefit entire health systems, significantly boosting the chances for a better life.
Rare diseases have helped launch many of the platforms that now define modern medicine. Their scientific complexity and the active engagement of rare-disease patient groups, who have long driven research, awareness, and data collection, have repeatedly pushed industry standards, scientists, and health systems to innovate earlier and more creatively than in other areas of medicine. Some of the earliest clinical successes in genomic sequencing, mRNA technologies, antisense oligonucleotides, RNA interference and gene therapy occurred in rare, single-gene disorders.
These breakthroughs have thus laid the groundwork for innovations now applied broadly across other areas of healthcare, including more common non-communicable diseases (NCDs) such as cancer, cardiometabolic disorders and other infectious diseases.
Emerging technologies also seem to be following a similar trajectory. Artificial intelligence, for example, is actively being tested in rare diseases because the challenges of small populations, fragmented data, and complex phenotypes require new analytical approaches.
How Gene Therapy Works
Genes are small segments of DNA that instruct your cells to make certain proteins when specific conditions are met.Mutated genes, on the other hand, may cause your cells to make too much or too little of the necessary protein. Even small changes can have a domino effect across your body, similar to how tiny changes in a computer code can affect an entire program.
Gene therapy can address this issue by:
- replacing the missing or " broken” gene with a working copy.
- turning off the malfunctioning genes.
- adding genes to immune cells to help them better target diseased cells.
In simpler terms, gene therapy works by altering the genetic code in order to help recover the functions of critical proteins. Proteins are vital aspects of the cell and also the structural basis of the body’s tissues. The instructions for making proteins are carried in a person’s genetic code, and any variants, or mutations, in this code can impact the production or function of proteins that may be critical to how the body works. Fixing or compensating for these disease-causing genetic changes may help to recover the role of these important proteins and allow the body to function as normally expected.
Types of Gene Therapy
There are two types of gene therapy:
- In vivo (takes place inside your body): Scientists put the vector carrying the new genes directly into your body via an injection or intravenous (IV) infusion.
- Ex vivo (takes place outside your body): Scientists extract cells from your body and introduce them to the vector inside a petri dish. Then, your altered cells are returned to your body, where they’ll hopefully multiply.
Multiple Methods of Gene Therapy
- Viral Vectors: Certain viruses are used as vectors due to the fact that they can deliver the material by infecting the cell. These viruses are modified so they cannot cause any disease when used in people. Some types of viruses, such as retroviruses, integrate their genetic material (including the new gene) into a chromosome in the human cell. Other viruses, such as adenoviruses, introduce their DNA into the nucleus of the cell, but the DNA is not integrated into a chromosome. Viruses can also deliver the gene-editing tools to the nucleus of the cell.
- AAV Vectors: AAVs are small viruses (~25 nm) from the Dependoparvovirus genus that require a helper virus, such as adenovirus or herpes simplex virus, to replicate. In the absence of a helper, they remain dormant and non-pathogenic, making them exceptionally safe for gene delivery applications. Recombinant AAVs (rAAVs) are engineered without the Rep gene, thus allowing them to persist episomally in host cells without integrating into the genome, which minimizes the risk of insertional mutagenesis and enhances safety in gene therapy.
- Lipid Nanoparticles: Lipid nanoparticles are tiny fat-based capsules that can shuttle genetic material into cells. This is the same technology behind some mRNA vaccines. Lipid nanoparticles work well for delivering gene-editing tools like CRISPR to the liver, but redirecting them to other tissues is proven to be difficult.
- Extracellular Vesicles: In this method, tiny bubbles are naturally released by cells. As they are biological in origin, they tend to be better tolerated by the immune system and are able to protect their cargo from being destroyed in the bloodstream. Some, particularly those derived from stem cells, are even equipped with natural anti-inflammatory properties. This area is still in its early stages, but extracellular vesicles may eventually allow repeated doses of gene therapy without escalating immune reactions.
- CAR-T cell therapy: Chimeric antigen receptor T-cell (CAR-T) therapy involves the ex vivo genetic modification of the patient’s T-cells to express the receptors that can target tumor-specific antigens. FDA-approved products, such as Kymriah and Yescarta, have already demonstrated improved therapeutic outcomes in blood cancers.
Gene Therapy vs Traditional Medicines
Genetic medicine and traditional medicine both aim to improve health and treat diseases, but they do differ in terms of their approaches. Genetic medicine focuses on understanding how genes and genetic variations influence an individual's risk of developing certain diseases and tailoring treatments based on this information.
Traditional medicine, on the other hand, focuses on treating symptoms and diseases without necessarily considering what the underlying genetic factors are. While both fields have their strengths, genetic medicine has the potential to revolutionize healthcare by providing more personalized and targeted treatments based on an individual's unique genetic makeup.
While genetic medicine and traditional medicine have distinct approaches, they both play crucial roles in healthcare delivery and patient care. Genetic medicine offers a more personalized and targeted approach to disease management, while traditional medicine provides us with a broad spectrum of treatments for various health conditions. Both fields can complement each other and work together in order to help enhance patient outcomes and advance medical knowledge.
- Genetic medicine focuses on the role of genetics in health and disease, while traditional medicine emphasizes evidence-based practices.
- Genetic medicine offers personalized treatment plans based on an individual's genetic profile, whereas traditional medicine uses established protocols for disease management.
- Both genetic medicine and traditional medicine aim to improve patient outcomes and quality of life through effective treatments and interventions.
- Genetic medicine has the potential to revolutionize healthcare by offering more precise and targeted therapies, while traditional medicine continues to evolve with new advancements and technologies.
Recent FDA Approvals and Breakthroughs
We are seeing a big leap in gene therapy in recent times. Recent published reports and medical journals tell us that over 40 FDA-approved cell and gene therapies will be available by 2025. These treatments are varied, from CAR T-cell therapies to treatments for complex diseases like sickle cell disease.
FDA-Approved CAR T-Cell Therapy Products
The field of cancer treatment has seen a big change with FDA-approved CAR T-cell therapies. These treatments have shown great promise in fighting blood cancers. They offer new hope to patients and doctors.
CAR T-cell therapy uses a patient’s T-cells, which are changed to fight cancer. This personalized method has led to great results in trials. It’s a key reason the FDA has approved several CAR T-cell therapies.
Kymriah (Tisagenlecleucel) for ALL and DLBCL: Kymriah, made by Novartis, was the first CAR T-cell therapy approved by the FDA. It helps treat certain cases of acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). Kymriah has shown it can be very effective in trials, giving patients a chance at a cure.
Yescarta (Axicabtagene Ciloleucel) for Lymphomas: Yescarta, from Kite Pharma (Gilead Sciences), is another FDA-approved CAR T-cell therapy. It’s mainly for treating certain lymphomas, like DLBCL. Yescarta has shown strong results in trials, adding to the treatment options for patients with relapsed or refractory lymphomas. For more info on CAR T-cell therapies, check out Targeted Oncology.
Tecartus (Brexucabtagene Autoleucel) for MCL and ALL: Tecartus is a CAR T-cell therapy approved for treating mantle cell lymphoma (MCL) and some ALL cases. Made by Kite Pharma, Tecartus has shown it works well in trials. It offers a new treatment option for patients with these conditions.
Breyanzi (Lisocabtagene Maraleucel) for LBCL: Breyanzi, from Bristol Myers Squibb (Juno Therapeutics), is for treating certain large B-cell lymphoma (LBCL). Breyanzi has shown promising results in trials. It gives patients a potentially effective treatment option.
Gene Therapy Products for Rare Genetic Disorders
Gene therapy has changed how we treat rare genetic disorders. It brings new hope to patients around the world. Recent approvals have marked big steps forward in this field.
Luxturna (Voretigene Neparvovec) for Inherited Retinal Disease: Luxturna is a gene therapy for inherited retinal disease caused by RPE65 gene mutations. It gives retinal cells a normal RPE65 gene, helping restore vision. Clinical trials show big improvements in vision for those treated, with lasting benefits.
Zolgensma (Onasemnogene Abeparvovec) for Spinal Muscular Atrophy: Zolgensma is a gene therapy for spinal muscular atrophy (SMA). It uses an adeno-associated virus (AAV) vector to replace the SMN1 gene. It greatly improves motor function and survival in SMA infants. The treatment is a single intravenous infusion, a game-changer for SMA patients.
Roctavian (Valoctocogene Roxaparvovec) for Hemophilia A: Roctavian is a gene therapy for Hemophilia A. It delivers a functional F8 gene to liver cells, enabling factor VIII production. Clinical trials show a big drop in bleeding episodes for treated patients, improving their lives.
Hemgenix (Etranacogene Dezaparvovec) for Hemophilia B: Hemgenix is a gene therapy for Hemophilia B. It delivers a normal F9 gene to liver cells, boosting factor IX production. Patients treated with Hemgenix see a big drop in bleeding events, showing its promise.
Revolutionary Sickle Cell Disease Gene Therapy Products
The approval of new gene therapies is a big step forward in treating sickle cell disease. These treatments bring new hope to those with this serious genetic disorder.
Casgevy (Exagamglogene Autotemcel) – CRISPR-Based Therapy: Casgevy is a pioneering gene therapy that uses CRISPR to fix the patient’s genes. Its innovative approach has shown great promise in clinical trials. It offers a new way to treat the disease.
Lyfgenia (Lovotibeglogene Autotemcel) – Lentiviral Vector Therapy: Lyfgenia is another FDA-approved gene therapy. It uses a lentiviral vector to change the patient’s genes. This therapy has shown it can greatly reduce sickle cell disease symptoms. It improves patients’ quality of life.
The Future of Gene Therapy
The future of gene therapy is filled with promise and quite a lot of potential. As researchers, scientists, and medical professionals all over the world continue to delve into the complexities of genetics, we can expect remarkable breakthroughs in the treatment of diseases that were once considered incurable. The journey ahead will require a high amount of collaboration, ethical reflection, research, and a commitment in order to ensure that these revolutionary therapies become accessible to all who need them.
Prospects in gene therapy include:
- Vector capacity engineering: Advancements in the engineering of high-capacity delivery vectors and hybrid delivery platforms can accommodate genes of longer length or packaging of genes in the same delivery vehicle for multiple treatable genetic conditions, further revolutionizing gene therapy.
- Delivery specificity optimization: The achievement of cell-type-specific gene expression material is one of the major upcoming priorities for enhanced specificity and effectiveness. Tissue-specific promoters, refined vector capsid design, and targeted delivery systems are essential to enhance the precision of gene therapy in intended cell populations.
- Mitigating immune responses: Future directions regarding the immunogenic effects of viral vectors and the target gene are a significant gap. Immune-evasive viral capsids and low-immunogenic nanoparticles based on non-viral delivery methods are potential strategies for future clinical applications.
- Application in common diseases: Beyond rare disorders, research is expanding to diseases like cardiovascular diseases, neurodegenerative diseases, and infectious diseases.
- Personalized therapy and AI integration: Artificial intelligence and machine learning platforms are being used for enhanced personalized gene therapies based on an individual’s genetic profile.
Final Thoughts
Gene therapy has moved from foundational rDNA technology into clinical applications across genetic and acquired diseases in recent times. The developments in vector engineering, gene editing platforms, and regulatory frameworks have significantly improved the precision, safety, and durability of gene therapy. With its ongoing prospects, gene therapy is set to be highly significant in the future of medicine and therapeutics.
The future of gene therapy is likely to be shaped by emerging trends and innovations in gene editing technologies, RNA-based therapies, and personalized medicine. As the field continues to evolve, we can expect to see new and exciting developments that will help to improve treatment outcomes and expand the range of diseases that can be treated.
About the Authors
Aditi Shivarkar
Aditi, Vice President at Precedence Research, brings over 15 years of expertise at the intersection of technology, innovation, and strategic market intelligence. A visionary leader, she excels in transforming complex data into actionable insights that empower businesses to thrive in dynamic markets. Her leadership combines analytical precision with forward-thinking strategy, driving measurable growth, competitive advantage, and lasting impact across industries.
Aman Singh
Aman Singh with over 13 years of progressive expertise at the intersection of technology, innovation, and strategic market intelligence, Aman Singh stands as a leading authority in global research and consulting. Renowned for his ability to decode complex technological transformations, he provides forward-looking insights that drive strategic decision-making. At Precedence Research, Aman leads a global team of analysts, fostering a culture of research excellence, analytical precision, and visionary thinking.
Piyush Pawar
Piyush Pawar brings over a decade of experience as Senior Manager, Sales & Business Growth, acting as the essential liaison between clients and our research authors. He translates sophisticated insights into practical strategies, ensuring client objectives are met with precision. Piyush’s expertise in market dynamics, relationship management, and strategic execution enables organizations to leverage intelligence effectively, achieving operational excellence, innovation, and sustained growth.